Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of AL101 in Adenoid Cystic Carcinoma with Activating Notch Mutations
2019-000309-64Phase 2Unknown
- Sponsor
- Ayala Pharmaceuticals, Inc.
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osugacestat in adenoid cystic carcinoma (ACC), sponsored by Ayala Pharmaceuticals, Inc. Primary endpoint: Objective response rate (ORR) by RECIST v1.1. Status: unknown.
02
Drugs
osugacestat
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on 2019-000309-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000309-64.